NF1 and glioblastoma: The prevalence of NF1 somatic mutations in sporadic GBMs was initially estimated to be approximately 15%, with a subsequent study by The Cancer Genome Atlas (TCGA) network reporting aberrations in at least 23% (47 out of 206) of human GBM samples when both NF1 inactivating mutations and deletions (including heterozygous deletions) were analysed [93, 94].